Opinion|Videos|July 10, 2024

Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024

Dr Garfall, MD, provides insights following results derived from the MajesTEC-1 study.

Video content above is prompted by the following:

  • Discuss the data you presented at the 2024 ASCO Annual Meeting on long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM).
    • What was the objective of this study?
    • How was this study designed/what methodology was used?
    • What results were presented?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo